N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide

US8012988B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Hans Allgeier
• Yves Auberson · Allschwil, CH
• David Carcache · Binningen, CH
• Philipp Floersheim · Basel, CH
• Christel Guibourdenche · Aesch, CH
• Wolfgang Froestl · Ecublens, CH
• Jörg Kallen · Basel, CH
• Manuel Koller · Köniz, CH
• Henri Mattes · Montfort-sur-Argens, FR
• Joachim Nozulak · Heitersheim, DE
• David Orain · Hésingue, FR
• Johanne Renaud · Bellinzona, CH

Key dates

• Filing date: Sep 29, 2009
• Grant date: Sep 6, 2011
• Expiry date: Sep 29, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I)wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.